

Surrey & North West Sussex Area Prescribing Committee (APC)

Policy Statement	Mexilitene (Namuscla®) for the management of drug resistant ventricular arrhythmia (off-label)
Policy No:	APC 444-2019
Date of Issue	August 2019
Review Date:	August 2022 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations:	
<p>The Surrey and North West Sussex Area Prescribing Committee approves the prescribing of mexilitene (Namuscla®) for the management of drug resistant mexilitene for ventricular arrhythmia when initiated and continued by a specialist.</p> <p>The APC recommend a RED traffic light status for the use of mexilitene for this indication.</p> <p>All patients currently being prescribed mexilitene in primary care should be referred into a cardiologist for specialist review and a switch to Namuscla®. Responsibility for prescribing must remain with the specialist.</p> <p>Those patients being prescribed mexilitene 'special formulations' will be switched to Namuscla® (a licensed product) by the cardiologists.</p>	
Key Considerations:	
<ul style="list-style-type: none"> • Mexilitene off label use for this indication. • Mexilitene 'specials' formulations requiring specialist input in transferring to a licensed product (Namuscla®) • Long term ongoing specialist monitoring of toxicity. • Access to substantially discounted price in secondary care. • Its potential to precipitate life threatening ventricular tachyarrhythmia 	
Date taken to Area Prescribing Committee	7 th August 2019
Agreed by APC members	27 th August 2019

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG